E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Usefulness of tirofiban among Patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)
David A. Morrow,Marc S. Sabatine,Elliott M. Antman,Christopher P. Cannon,Eugene Braunwald,Pierre Théroux +5 more
TL;DR: In high-risk patients treated without PCI, tirofiban reduced the risk for death, myocardial infarction, and refractory ischemia at 30 days, and this benefit was similar in magnitude as that for patients who underwent PCI.
Journal ArticleDOI
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Jan Steffel,Christian T. Ruff,Ophelia Yin,Eugene Braunwald,Jeong-Gun Park,Sabina A. Murphy,Stuart J. Connolly,Elliott M. Antman,Robert P. Giugliano +8 more
TL;DR: In this paper, a pre-specified analysis of the ENGAGE AF-TIMI 48 trial, comparing patients on LDER versus HDER was performed, and the secondary and tertiary pre-defined NCOs were similar between the two dosing regimens.
Journal ArticleDOI
Pathogenesis and pathology of coronary heart disease syndromes.
Paul M. Ridker,Elliott M. Antman +1 more
TL;DR: Understanding current concepts in the pathogenesis and pathology of atherosclerosis is fundamental for physicians concerned with coronary care.
Journal ArticleDOI
Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction.
Owen Mogabgab,Robert P. Giugliano,Marc S. Sabatine,Christopher P. Cannon,Satishkumar Mohanavelu,Stephen D. Wiviott,Elliott M. Antman,Eugene Braunwald +7 more
TL;DR: In this paper, the authors explored the relationship between variation of symptom onset, patient characteristics, and outcomes in two worldwide fibrinolytic trials, and correlated timing with patient characteristics and outcomes (adjusted for thrombolysis in myocardial infarction [TIMI] risk score).
Journal ArticleDOI
Underutilization of Evidence-Based Medications in Acute ST Elevation Myocardial Infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry
Christopher P. Cannon,Maria Cecilia Bahit,J. Mark Haugland,Timothy D. Henry,Marc J. Schweiger,George R. McKendall,Prediman K. Shah,Sabina A. Murphy,C. Michael Gibson,Carolyn H. McCabe,Elliott M. Antman,Eugene Braunwald +11 more
TL;DR: It is found that reperfusion therapy was underused, with only 69% of patients with STEMI receiving this proven treatment, and of those only 25% treated within the recommended timeline.